Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The classification of human epidermal growth factor receptor 2 (HER2) status is evolving beyond HER2-positive and HER2-negative.
• The emergence of the
• HER2-low
• category necessitates novel therapeutic strategies.
• Resistance to existing HER2-targeted therapies presents a significant clinical challenge.

Purpose of the Study:

• To review current and emerging treatment strategies for HER2-positive and HER2-low breast cancer.
• To explore approaches for overcoming resistance to HER2-targeted therapies.
• To discuss the role of targeting other members of the HER family.

Main Methods:

• Review of current literature on HER2-targeted therapies and resistance mechanisms.
• Analysis of novel therapeutic agents, including antibody drug conjugates (ADCs) and tyrosine kinase inhibitors.
• Exploration of combination treatment strategies involving downstream signaling pathways (PI3K/AKT/mTOR).

Main Results:

• New HER2 antibody drug conjugates (ADCs) demonstrate potential efficacy in HER2-low breast cancer.
• Tyrosine kinase inhibitors like tucatinib and neratinib offer alternative treatment options.
• Combined therapies targeting HER2-associated pathways may overcome treatment resistance.
• Targeting other HER family members presents a promising avenue for improved patient outcomes.

Conclusions:

• The treatment landscape for HER2-expressing breast cancers is expanding to include HER2-low disease.
• Overcoming resistance to HER2-targeted therapies requires multifaceted strategies, including combination treatments and targeting alternative pathways.
• Targeting the broader HER family holds potential for enhancing therapeutic efficacy in breast cancer.